LATS2 and serous adenocarcinoma: These results are discrepant to those from the previous study by Xu et al. who reported that LATS1 and LATS2 expression was elevated in mucinous compared to serous ovarian carcinomas, correlated with better outcome (longer survival and less recurrence), decreased with higher FIGO stage, and was elevated in high-grade serous carcinomas (Xu et al. 2015).